First Typhoid vaccine promising long-term protection launched by Bharat Biotech
Hyderabad based Bharat Biotech launched world’s first clinically proven typhoid conjugate vaccine, Typbar – TCV.
How Typbar-TCY is different from existing vaccines?
- Typbar-TCV has a sharp edge over the existing typhoid vaccines as the latest conjugate vaccine provides long-term protection — for about 10 years — with a single dose.
World over around 200 lakh people are affected annually by typhoid, out of which around 2 lakh die. About 62% of these were in Pakistan and India.
Categories: Business, Economy & Banking